New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
08:22 EDTCPRXCatalyst Pharmaceutical completes patient enrollment for Firdapse Phase 3 trial
Catalyst Pharmaceutical Partners announced that it has reached the patient enrollment target for its pivotal Phase 3 trial evaluating the safety and efficacy of Firdapse for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome, or LEMS. Based on the enrollment and randomization success metrics achieved to date, the Company believes that it has enrolled a sufficient number of LEMS patients to ensure that 36 patients will be randomized into the double-blind, placebo-controlled, discontinuation portion of the trial.
News For CPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
09:05 EDTCPRXCatalyst Pharmaceutical should be bought on weakness, says SunTrust
Subscribe for More Information
April 24, 2015
16:56 EDTCPRXCatalyst director Charles O'Keeffe buys 5,000 shares of common stock
Subscribe for More Information
14:44 EDTCPRXCatalyst slips after competitor surprises with positive data, TheStreet says
Shares of Catalyst Pharmaceutical are falling after its privately held competitor, Jacobus Pharmaceuticals, surprised with the disclosure of positive clinical trial data showing "unequivocal evidence" that its experimental drug is an effective treatment for patients with Lambert-Eaton Myasthenic Syndrome, said TheStreet's Adam Feuerstein. Jacobus Pharma's drug, which can now reportedly be submitted to FDA for approval, has the same active ingredient as in Firdapse, the report added. Shares of Catalyst are down about 17% to $3.88 in afternoon trading. Reference Link
14:33 EDTCPRXCatalyst Pharmaceutical weakness a buying opportunity, says Piper Jaffray
Piper Jaffray expects Catalyst Pharmaceutical's Firdapse to gain approval first and secure Orphan designation for Lambert-Eaton myasthenic syndrome. The firm reiterates its Overweight rating and $7 price target and would be buyers on weakness.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use